登录新浪财经APP 搜索【信披】查看更多考评等级 2020年6月30日，本公司与子公司南京安赛莱医药科技有限公司、广发银行股份有限公司扬州分行、中 国建设银行股份有限公司南京鼓楼支行和华泰联合证券签署《募集资金专户存储五方监管协议》,在广 发银行股份有限公司扬州分行开设募集资金专项账户(账号：9550880058239300203),在中国建设银行股 份有限公司南京鼓楼支行(建宁路支行)开设募集资金专项账户(账号：32050159524609999996)。 2020年6月30日，本公司与子公司扬州艾迪医药科技有限公司、江苏银行股份有限公司扬州分行和华泰 联合证券签署《募集资金专户存储四方监管协议》,在江苏银行股份有限公司扬州分行(唐城支行)开设募 集资金专项账户(账号：90160188000125327)。 2022年1月19日，公司召开第一届董事会第二十一次会议和第一届监事会第十七次会议，审议通过了 《关于变更部分募集资金专项账户及新增募集资金专项账户的议案》。 2022年1月26日，本公司与中国建设银行股份有限公司江苏省分行和华泰联合证券签署《募集资金专户 存储三方监管协议》,在中国建设银行股份有限公司 ...

1月13日多瑞医药大宗交易一览 | 成交量（万 | 成交金额（万 | 成交价格 | 相对当日收盘折溢价 | 买方营业 | 卖方营业 | | --- | --- | --- | --- | --- | --- | | 股） | 元） | （元） | （%） | 部 | 部 | | 12.50 | 696.13 | 55.69 | 0.00 | 机构专用 | 机构专用 | 多瑞医药1月13日大宗交易平台出现一笔成交，成交量12.50万股，成交金额696.13万元，大宗交易成交 价为55.69元。该笔交易的买卖双方均为机构专用席位。 证券时报·数据宝统计显示，多瑞医药今日收盘价为55.69元，下跌0.73%，日换手率为1.55%，成交额为 7020.52万元，全天主力资金净流出124.66万元，近5日该股累计下跌1.19%，近5日资金合计净流出 1951.85万元。 两融数据显示，该股最新融资余额为2.02亿元，近5日减少1187.28万元，降幅为5.54%。 据天眼查APP显示，西藏多瑞医药股份有限公司成立于2016年12月22日，注册资本8000万人民币。（数 据宝） （文章来源：证券时报网） ...

Group 1 - The company, Jiangsu Aidi Pharmaceutical Group Co., Ltd., plans to raise up to 185 million yuan through a simplified procedure to issue A-shares, primarily to acquire a 22.23% stake in its subsidiary, Nanjing Nanda Pharmaceutical Co., Ltd., for approximately 130 million yuan, and to supplement working capital with 55 million yuan [1] - Nanda Pharmaceutical specializes in thrombolytic drugs and low molecular weight heparin raw materials, making it one of the few integrated manufacturers in China holding production approvals for both raw materials and injectable formulations [2] - The acquisition of Nanda Pharmaceutical is expected to enhance the company's control over it, optimize financial performance, and maximize synergies, thereby strengthening its competitive position in the human protein sector [3] Group 2 - The stroke incidence in China is rising, with acute ischemic stroke cases projected to increase from 4.1 million in 2023 to 4.9 million by 2027, highlighting a significant unmet clinical need for effective stroke treatments [3] - The market for neuroprotective drugs in China is expected to grow from 11.5 billion yuan in 2024 to 16.9 billion yuan by 2030, and further to 26.2 billion yuan by 2035, indicating a strong demand for innovative stroke medications [3] - Aidi Pharmaceutical has maintained rapid growth in the HIV sector for three consecutive years, with the market for anti-HIV drugs in China estimated at 7 billion yuan in 2023, projected to exceed 11 billion yuan by 2027 [4] Group 3 - The company is advancing its core HIV pipeline and aims to establish a comprehensive commercialization system for new HIV drugs, addressing the significant challenge posed by the large population of HIV-infected individuals in China [4] - Aidi Pharmaceutical has made significant progress in its HIV drug pipeline, with new drugs like ACC017 and ADC118 entering clinical trials, and is also developing long-acting pre-exposure prophylaxis drugs [5] - The 55 million yuan raised will be used to support operational funding and accelerate the development of core research projects, ensuring the efficient rollout of a diverse and comprehensive HIV drug commercialization strategy [5]

Group 1 - The core point of the article is that Huate Dain (000915) is set to officially launch its melatonin granule product, Manlejing, for online sales on platforms like Alibaba and JD this week, following prior interest reservations [1] - The product will also gradually enter hospitals across various regions in China for sales [1]

Core Viewpoint - The company reported a decline in profits for the third quarter due to routine maintenance in the chemical medicine workshop, the seasonal downturn in industry consumption, increased production capacity from the launch of the sixth phase project, and promotional discounts offered by the company [2] Group 1 - The main reasons for the profit decline include routine maintenance, seasonal consumption downturn, increased production capacity, and promotional discounts [2] - The company raised the price of gold mycin in domestic and other export markets at the end of November, which may positively impact the fourth quarter's performance [2] - Investors are advised to monitor the company's announcements for specific operational updates [2]

证券日报网讯1月13日，华特达因（000915）在互动平台回答投资者提问时表示，公司褪黑素颗粒产品 曼乐静本周即可在阿里和京东线上根据医生处方购买，后续将陆续进入国内各地医院销售。 ...

格隆汇1月13日丨艾迪药业(688488.SH)公布2026年度以简易程序向特定对象发行A股股票预案，本次发 行募集资金总额不超过（含）18,500.00万元，符合以简易程序向特定对象发行股票的募集资金总额不超 过人民币三亿元且不超过最近一年末净资产百分之二十的规定；扣除发行费用后的募集资金净额将用于 以下项目：收购南大药业22.2324%股权、补充流动资金。 MACD金叉信号形成，这些股涨势不错！ ...

2026年1月13日，山西仟源医药集团股份有限公司（以下简称"仟源医药"）发布公告称，公司第五届董 事会第三十六次会议审议通过了《关于回购注销2025年限制性股票激励计划部分限制性股票的议案》。 因2名激励对象离职不再具备激励资格，公司拟回购注销其已获授但尚未解除限售的限制性股票合计 5.00万股，回购价格为授予价格5.6元/股并支付银行同期定期存款利息，资金来源为公司自有资金。 回购背景及原因 据公告披露，仟源医药于2025年实施了2025年限制性股票激励计划（以下简称"本次激励计划"）。根据 《激励计划》相关规定，"激励对象离职的，包括主动辞职、合同到期且因个人原因不再续约、因个人 过错被公司解聘等，自离职之日起，激励对象已解除限售的限制性股票不作处理，已获授但尚未解除限 售的限制性股票不得解除限售，由公司按授予价格回购注销，并支付银行同期定期存款利息。" 此次涉及回购注销的2名激励对象因离职已不具备激励对象资格，因此公司依据《激励计划》启动回购 注销程序，拟回购注销其持有的尚未解除限售的限制性股票。 回购具体情况 回购数量 根据《激励计划》及董事会决议，本次回购价格为授予价格5.6元/股，并将按银行同期 ...

Core Viewpoint - Hendi Pharmaceutical (301211) forecasts a significant decline in net profit for 2025, estimating a range of 31 million to 39 million yuan, representing a year-on-year decrease of 57.4% to 66.14% [2] Group 1: Financial Performance - The company anticipates a net profit of 31 million to 39 million yuan for 2025, indicating a substantial decline compared to previous years [2] - The projected decline in net profit is attributed to intensified market competition for its main product, ibuprofen raw materials, and certain specialty raw materials, leading to a decrease in gross margin [2] Group 2: Market Conditions - Increased competition in the market for ibuprofen and specialty raw materials is a key factor contributing to the expected decline in profitability [2] - A reduction in interest income from cash management due to falling interest rates is also impacting the company's financial outlook [2]

每经讯，2026年1月13日，北交所上市公司新赣江（920367，收盘价：30.55元）登上龙虎榜，交易方式是连续竞价，披露原因是 当日收盘价涨幅达到30.00%，成交数量896.48万股，成交金额2.71亿元。买一席位为国泰海通证券股份有限公司上海江苏路营业 部，买入1326.18万元；卖一席位为天府证券有限责任公司上海崂山路证券营业部，卖出947.05万元。 | | 2026-01-13新贛江 (920367) 龙虎榜 | | | | --- | --- | --- | --- | | 序号 | 交易营业部名称 | 买入金额(元) | 卖出金额(元) | | नेट ग | 国泰海通证券股份有限公司上海江苏路营业部 | 13261755 | 1869195.4 | | 买2 | 方正证券股份有限公司长沙黄兴中路证券营业部 | 11422645 | 198750 | | 址3 | 上海证券有限责任公司宁波北仑新大路证券营业部 | 7412897.65 | 0 | | ग्रेट प | 东亚前海证券有限责任公司深圳分公司 | 6826601.35 | 0 | | ન્નેર | 东莞证券股份有限公司大连星海 ...